Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 20/20 | 0.90 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.90 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.90 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.90 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29063029 | 0.99 | ALOX5AP (0.88) | ALOX5APPTGS1ALOX5LTC4SCYP2C9 | |
| SCHEMBL1722524 | 0.94 | ALOX5AP (1.00) | ALOX5APPTGS1ALOX5LTC4S | |
| Fiboflapon SCHEMBL29723363 | 0.94 | ALOX5AP (1.00) | ALOX5APPTGS1ALOX5LTC4SCYP2C9 | |
| Fiboflapon SCHEMBL29379276 | 0.94 | ALOX5AP (1.00) | ALOX5APPTGS1ALOX5LTC4SCYP2C9 | |
| Fiboflapon SCHEMBL11820 | 0.94 | ALOX5AP (1.00) | ALOX5APPTGS1ALOX5LTC4SCYP2C9 | |
| Fiboflapon SCHEMBL28358195 | 0.94 | ALOX5AP (0.99) | ALOX5APPTGS1ALOX5LTC4SCYP2C9 | |
| Fiboflapon SCHEMBL1254873 | 0.94 | ALOX5AP (0.99) | ALOX5APPTGS1ALOX5LTC4SCYP2C9 | |
| Fiboflapon SCHEMBL29504643 | 0.94 | ALOX5AP (0.99) | ALOX5APPTGS1ALOX5LTC4SCYP2C9 | |
| SCHEMBL29617637 | 0.93 | ALOX5AP (0.78) | ALOX5APPTGS1ALOX5LTC4SCYP2C9 | |
| SCHEMBL19924847 | 0.93 | ALOX5AP (0.78) | ALOX5APPTGS1ALOX5LTC4SCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200147064-A1 | Reduction of Pro-Inflammatory HDL Using a Leukotriene Inhibitor | AUTOIMMUNE PHARMA LLC (US) | 2020-05-14 | — | — | US | claimed |
| WO-2018152405-A1 | REDUCTION OF PRO-INFLAMMATORY HDL USING A LEUKOTRIENE INHIBITOR | AUTOIMMUNE PHARMA LLC (US) | 2018-08-23 | — | — | WO | claimed |
| EP-1943219-B8 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | PANMIRA PHARMACEUTICALS LLC (US) | 2012-03-07 | — | — | EP | claimed |
| EP-2404904-A1 | 5-lipoxygenase-activating protein (FLAP) inhibitors | Amira Pharmaceuticals, Inc. (US) | 2012-01-11 | — | — | EP | claimed |
| US-7977359-B2 | 5-lipdxygenase-activating protein (FLAP) inhibitors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-07-12 | — | — | US | claimed |
| JP-4705986-B2 | — | — | 2011-06-22 | — | — | JP | claimed |
| US-20090192171-A1 | 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors | AMIRA PHARMACEUTICALS, INC. (US) | 2009-07-30 | — | — | US | claimed |
| EP-1943219-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | Amira Pharmaceuticals, Inc. (US) | 2008-07-16 | — | — | EP | claimed |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | US | claimed |
| WO-2007056021-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-18 | — | — | WO | claimed |
| US-20070105866-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | claimed |
| US-20200147064-A1 | Reduction of Pro-Inflammatory HDL Using a Leukotriene Inhibitor | AUTOIMMUNE PHARMA LLC (US) | 2020-05-14 | — | — | US | disclosed |
| WO-2018152405-A1 | REDUCTION OF PRO-INFLAMMATORY HDL USING A LEUKOTRIENE INHIBITOR | AUTOIMMUNE PHARMA LLC (US) | 2018-08-23 | — | — | WO | disclosed |
| US-8710081-B2 | 5-lipoxygenase-activating protein (FLAP) inhibitors | PANMIRA PHARMACEUTICALS, LLC (US) | 2014-04-29 | — | — | US | disclosed |
| US-20140018394-A1 | 5-LIPOXGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AUTOIMMUNE PHARMA LLC | 2014-01-16 | — | — | US | disclosed |
| US-20090192171-A1 | 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors | AMIRA PHARMACEUTICALS, INC. (US) | 2009-07-30 | — | — | US | disclosed |
| EP-1943219-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | Amira Pharmaceuticals, Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | US | disclosed |
| WO-2007056021-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105866-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105866-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | ALOX5AP 4/4885PTGS1 27/4885ALOX5 1/4885 |
| US-20200147064-A1 | Reduction of Pro-Inflammatory HDL Using a Leukotriene Inhibitor | LTB4R, LTC4S, LTB4R2 | ALOX5AP 35/4885PTGS1 22/4885ALOX5 7/4885 |
| US-20090192171-A1 | 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors | ALOX5, ALOX15B, ALOX15 | ALOX5AP 4/4885PTGS1 27/4885ALOX5 1/4885 |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | ALOX5AP 4/4885PTGS1 27/4885ALOX5 1/4885 |
| US-20140018394-A1 | 5-LIPOXGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, LTA4H, ALOX5AP | ALOX5AP 3/4885PTGS1 38/4885ALOX5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.